A kemoterápia okozta hányás csillapítása

Translated title of the contribution: Prophylaxis of chemotherapy-induced vomiting and nausea

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Chemotherapy-induced vomiting and nausea is the most common adverse event of anticancer therapy. In different guide-lines (MASCC, NCCN, ESMO and ASCO) antiemetic prophylaxis is directed toward the emetogenic potential of the chemotherapy and the type of vomiting and nausea. Chemotherapeutic agents are classified into four emetic risk groups: high, moderate, low, and minimal. Steroids, dexamethasone, metoclopramide, cannabinoids, benzodiazepines, 5-HT3 receptor antagonists (ondansetron, granisetron, tropisetron) and a new group of antiemetics, the neurokinin1 receptor antagonists are used to prevent anticipatory, acute and delayed vomiting and nausea. This paper examines evidence-based recommendations for optimal use of antiemetics.

Original languageHungarian
Pages (from-to)391-394
Number of pages4
JournalMagyar Onkologia
Volume52
Issue number4
DOIs
Publication statusPublished - 2008

Fingerprint

Antiemetics
Nausea
Vomiting
tropisetron
Drug Therapy
Granisetron
Emetics
Serotonin 5-HT3 Receptor Antagonists
Receptors, Serotonin, 5-HT3
Ondansetron
Metoclopramide
Cannabinoids
Benzodiazepines
Dexamethasone
Steroids
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A kemoterápia okozta hányás csillapítása. / Tóth, J.; Szántó, J.

In: Magyar Onkologia, Vol. 52, No. 4, 2008, p. 391-394.

Research output: Contribution to journalArticle

@article{51ef3f449c08483bb57d68b60670d6ff,
title = "A kemoter{\'a}pia okozta h{\'a}ny{\'a}s csillap{\'i}t{\'a}sa",
abstract = "Chemotherapy-induced vomiting and nausea is the most common adverse event of anticancer therapy. In different guide-lines (MASCC, NCCN, ESMO and ASCO) antiemetic prophylaxis is directed toward the emetogenic potential of the chemotherapy and the type of vomiting and nausea. Chemotherapeutic agents are classified into four emetic risk groups: high, moderate, low, and minimal. Steroids, dexamethasone, metoclopramide, cannabinoids, benzodiazepines, 5-HT3 receptor antagonists (ondansetron, granisetron, tropisetron) and a new group of antiemetics, the neurokinin1 receptor antagonists are used to prevent anticipatory, acute and delayed vomiting and nausea. This paper examines evidence-based recommendations for optimal use of antiemetics.",
keywords = "5-HT3 receptor antagonists, Chemotherapy-induced vomiting and nausea",
author = "J. T{\'o}th and J. Sz{\'a}nt{\'o}",
year = "2008",
doi = "10.1556/MOnkol.52.2008.4.9",
language = "Hungarian",
volume = "52",
pages = "391--394",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "4",

}

TY - JOUR

T1 - A kemoterápia okozta hányás csillapítása

AU - Tóth, J.

AU - Szántó, J.

PY - 2008

Y1 - 2008

N2 - Chemotherapy-induced vomiting and nausea is the most common adverse event of anticancer therapy. In different guide-lines (MASCC, NCCN, ESMO and ASCO) antiemetic prophylaxis is directed toward the emetogenic potential of the chemotherapy and the type of vomiting and nausea. Chemotherapeutic agents are classified into four emetic risk groups: high, moderate, low, and minimal. Steroids, dexamethasone, metoclopramide, cannabinoids, benzodiazepines, 5-HT3 receptor antagonists (ondansetron, granisetron, tropisetron) and a new group of antiemetics, the neurokinin1 receptor antagonists are used to prevent anticipatory, acute and delayed vomiting and nausea. This paper examines evidence-based recommendations for optimal use of antiemetics.

AB - Chemotherapy-induced vomiting and nausea is the most common adverse event of anticancer therapy. In different guide-lines (MASCC, NCCN, ESMO and ASCO) antiemetic prophylaxis is directed toward the emetogenic potential of the chemotherapy and the type of vomiting and nausea. Chemotherapeutic agents are classified into four emetic risk groups: high, moderate, low, and minimal. Steroids, dexamethasone, metoclopramide, cannabinoids, benzodiazepines, 5-HT3 receptor antagonists (ondansetron, granisetron, tropisetron) and a new group of antiemetics, the neurokinin1 receptor antagonists are used to prevent anticipatory, acute and delayed vomiting and nausea. This paper examines evidence-based recommendations for optimal use of antiemetics.

KW - 5-HT3 receptor antagonists

KW - Chemotherapy-induced vomiting and nausea

UR - http://www.scopus.com/inward/record.url?scp=59849112624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59849112624&partnerID=8YFLogxK

U2 - 10.1556/MOnkol.52.2008.4.9

DO - 10.1556/MOnkol.52.2008.4.9

M3 - Article

C2 - 19068468

AN - SCOPUS:59849112624

VL - 52

SP - 391

EP - 394

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 4

ER -